Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-16, Stock:PFE, The news for the past five days is as follows:
2018-08-09: NEWS1: ICU Medical, Inc. (ICUI) Q2 2018 Earnings Conference Call Transcript.NEWS2: Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses.NEWS3: Why Sangamo Therapeutics, Inc. Stock Is Popping Today.NEWS4: Why Sangamo Therapeutics, Inc. Stock Is Popping Today.NEWS5: Cabozantinib Expected to Be Exelixis’s Long-Term Growth Driver.NEWS6: Why Sangamo Therapeutics, Inc. Stock Is Popping Today.NEWS7: Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well.NEWS8: Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well.NEWS9: Why Amgen is a Top Socially Responsible Dividend Stock (AMGN).NEWS10: Why Amgen is a Top Socially Responsible Dividend Stock (AMGN).NEWS11: Analysts’ Recommendations for Pfizer on August 6.NEWS12: Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well.NEWS13: Examining Pfizer’s Valuation as of August 6.NEWS14: A Look at Recent Developments at Pfizer.
2018-08-10: NEWS1: GlycoMimetics Stock Has Substantial Upside.NEWS2: GlycoMimetics Stock Has Substantial Upside.NEWS3: Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...).NEWS4: Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...).NEWS5: After Hours Most Active for Aug 10, 2018 :  WMB, WPZ, PFE, ABEV, XOM, T, QQQ, MSFT, MAT, CMCSA, MCHI, INTC.NEWS6: After Hours Most Active for Aug 10, 2018 :  WMB, WPZ, PFE, ABEV, XOM, T, QQQ, MSFT, MAT, CMCSA, MCHI, INTC.NEWS7: GlycoMimetics Stock Has Substantial Upside.NEWS8: Mylan (MYL) Q2 2018 Earnings Conference Call Transcript.NEWS9: Noteworthy ETF Inflows: XLV, JNJ, UNH, PFE.NEWS10: Noteworthy ETF Inflows: XLV, JNJ, UNH, PFE.NEWS11: Corcept (CORT) Earnings and Revenues Miss Estimates in Q2.NEWS12: Corcept (CORT) Earnings and Revenues Miss Estimates in Q2.NEWS13: Pharma Stocks Are Starting to Look More Attractive.NEWS14: You Better Be Careful with Merck Stock, Especially at These Highs.NEWS15: In $270M Peninsula vaccine company buyout, small players look to be big shots.NEWS16: Carl Icahn Fires Shots at Express Scripts.
2018-08-13: NEWS1: XBIO To Report Phase 2 Data This Year, VNRX Abuzz, ATRS To Face FDA In Sep.NEWS2: XBIO To Report Phase 2 Data This Year, VNRX Abuzz, ATRS To Face FDA In Sep.NEWS3: Shire, Shionogi File NDA for Intuniv for Adults in Japan.NEWS4: Shire, Shionogi File NDA for Intuniv for Adults in Japan.NEWS5: Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses.NEWS6: Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses.NEWS7: How GlaxoSmithKline’s Segments Have Performed.NEWS8: How GlaxoSmithKline’s Valuation Compares with Peers’.NEWS9: CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades.NEWS10: CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades.NEWS11: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2018.NEWS12: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2018.
2018-08-14: NEWS1: Pfizer Expected to Report Robust EPS Rise in Fiscal 2018.NEWS2: How IBM’s Global Business Services Unit Is Doing.NEWS3: Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018.
2018-08-15: NEWS1: FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%.NEWS2: A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity.NEWS3: Buy Stocks That Are Down, Not Up, Here.NEWS4: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS5: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS6: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.NEWS7: Allergan plc. (AGN) Ex-Dividend Date Scheduled for August 16, 2018.NEWS8: 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug.NEWS9: Novo Nordisk’s Biopharmaceuticals Segment: An Update.NEWS10: What's Next for Spark Therapeutics.NEWS11: What's Next for Spark Therapeutics.NEWS12: What&apos;s Next for Spark Therapeutics.NEWS13: ViiV Healthcare: ATLAS Study Meets Primary Endpoint - Quick Facts.NEWS14: ViiV Healthcare: ATLAS Study Meets Primary Endpoint - Quick Facts.

Answer: Rise